UNASSIGNED: 123 Background: Lymph node ratio (LNR) is defined as the proportion of involved nodes over total number of nodes. The latter may be superior to TNM staging as a prognostic indicator in @entity0 treated surgically first. Pathological staging after neoadjuvant therapy (NAT) is based on the @entity5 ( @entity5 ) in breast and nodes. We hypothesized that LNR after NAT offers additional useful prognostic information. METHODS: @entity1 receiving NAT were identified through the Stanford Tumor Registry. Based on previously published classifications LNRs in node positive disease was classified as low (L) 0.01-0.2, intermediate (I) 0.21-0.65, and high (H) > 0.65. Other discriminant cut-off points were sought. Kaplan-Meier log-rank test was used for survival analysis. RESULTS: 105 node-negative and 92 node-positive cases were identified (2003 -2010). Median number of nodes examined was 13, range 2-40. LNR among the node-positive cohort varied from 0.03 to 1.0. The distribution of positive nodes for L was 1-4, for I 1-13, and for H 2-25. The 3-year DFS and @entity3012 were 94% and 98%, for node-negative cases, and 66% and 77% for node-positive @entity5 . Survival for L = 79% (median 55%); I = 56.2% (median 52%); and H = 55.6% (median 49%). Using 0.5 as a new discriminant, the 3 and 5-year @entity3012 for LNR < 0.5 was 78.1% and 69.9%, and for LNR > 0.5 was 52.2% and 39.8%, respectively (p = 0.02). CONCLUSIONS: LNR of 0.5 was found to discriminatefor survivalin @entity1 after NAT. This differs from the LNR categories defined for @entity1 who had surgery first. Further validation in larger dataset is warranted.

Lymph node ratio as prognostic after neoadjuvant therapy in XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['residual cancer burden', 'cancers', 'RCB'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
